Title  | Date  | Price |
|---|
Currently Druggable in Prostate Cancer
A Drug Target Competitive Analysis
| Sep 2008 |
£1,540 |
Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis
| Aug 2008 |
£1,540 |
MarketWatch: Cancer
| Aug 2008 |
£110 |
Global Cancer Treatment Forecast to 2012
| Aug 2008 |
£795 |
Cytology and Hpv Testing World Markets
| Jul 2008 |
£1,695 |
Cancer Personalized Medicine 2008
| Jul 2008 |
£2,425 |
Cancer Antibodies: Competitive Positioning for Success
| Jun 2008 |
£1,555 |
Cancer Vaccines: Aim and Shoot
| May 2008 |
£1,555 |
Cancer Therapeutics Markets
| May 2008 |
£1,935 |
Cancer Therapies: Technologies and Global Markets
| May 2008 |
£2,760 |
Cancer Diagnostic Testing World Markets
| Apr 2008 |
£1,935 |
Companion Diagnostics in Personalized Medicine and Cancer Therapy
| Apr 2008 |
£1,695 |
Cancer Liver Cancer
| Mar 2008 |
£800 |
Cancer Melanoma or Skin Cancer
| Mar 2008 |
£800 |
Cancer Multiple Myeloma
| Mar 2008 |
£800 |
Cancer Non-Hodgkin Lymphoma
| Mar 2008 |
£800 |
Cancer Kidney Cancer
| Mar 2008 |
£800 |
Cancer Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer
| Mar 2008 |
£800 |
Cancer Ovarian Cancer
| Mar 2008 |
£800 |
Cancer Pancreatic Cancer
| Mar 2008 |
£800 |
Cancer Head and Neck Cancer
| Mar 2008 |
£800 |
Cancer Gastrointestinal (Stomach) Cancer
| Mar 2008 |
£800 |
Cancer Colorectal Cancer or Colon Cancer
| Mar 2008 |
£800 |
Cancer Prostate Cancer
| Mar 2008 |
£800 |
Cancer Breast Cancer
| Mar 2008 |
£800 |
Cancer Brain Tumor
| Mar 2008 |
£800 |
Cancer Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia
| Mar 2008 |
£800 |
The Worldwide Market for Cancer Diagnostics
3rd Edition
| Mar 2008 |
£1,990 |
Cancer Cell Therapy Markets
| Mar 2008 |
£1,935 |
Cardiac Toxicity
| Mar 2008 |
£1,495 |
The Cancer Market Outlook to 2012
| Jan 2008 |
£1,995 |
Cancer Stem Cells
Emerging Therapeutic, Diagnostic and Market Opportunities (2008)
| Jan 2008 |
£1,600 |
Stakeholder Opinions: Head and Neck Cancer
| Nov 2007 |
£2,000 |
Who's Developing What in New Cancer Drugs?
| Nov 2007 |
£495 |
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology
| Nov 2007 |
£2,930 |
Pipeline Insight: Molecular Targeted Cancer Therapies Can anything else revolutionize the market?
- Cancer
| Oct 2007 |
£7,600 |
Pipeline Insight: Cancer Overview
Increasing Diversity Offers Both High Risk And Reward
| Sep 2007 |
£7,600 |
Cancer Vaccine Developments to 2013
| Sep 2007 |
£1,296 |
Decoding Big Pharmas R&D Strategy in Oncology
| Sep 2007 |
£2,930 |
Melanoma - Targeted Therapeutics
| Jul 2007 |
£1,555 |
Analytical Tool - Targeted Therapeutics: Melanoma
| Jul 2007 |
£2,470 |
Stakeholder Opinions: Primary Brain Cancer
| Jul 2007 |
£2,000 |
Commercial Insight: Top 20 Cancer Therapy Brands - Sales of targeted therapies overtake cytotoxics in 2006
| Jul 2007 |
£7,600 |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC
| Jul 2007 |
£4,125 |
Innovative And Targeted Cancer Therapies
Key Technologies, New Applications And Leading Players
| Jul 2007 |
£1,495 |
Antibody Drug Target Atlas in Oncology
| Jun 2007 |
£2,730 |
China Anti-tumor Drugs Market Report
2007
| Jun 2007 |
£150 |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
| Jun 2007 |
£4,125 |
Looking at the Cancer Therapy Market
| Jun 2007 |
£350 |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas
| Jun 2007 |
£4,125 |
Analytical Tool - Current & Future Lung Cancer Therapeutics
| May 2007 |
£2,470 |
Lymphoma Drug Pipeline Update 2007
| May 2007 |
£1,195 |
Immunotherapy in Oncology
Drug Pipeline Update 2007
| May 2007 |
£1,590 |
Leukemia Drug Pipeline Update 2007
| May 2007 |
£1,195 |
Hematological Cancers Drug Pipeline Update 2007
| May 2007 |
£1,590 |
Apoptosis in Oncology
Drug Pipeline Update 2007
| May 2007 |
£1,195 |
Prostate Cancer
Drug Pipeline Update 2007
| May 2007 |
£1,195 |
Ovarian Cancer Drug Pipeline Update 2007
| May 2007 |
£1,195 |
Analytical Tool - Breast Cancer Therapeutics & Competitive Insights
| May 2007 |
£2,470 |
Cancer Vaccines
Drug Pipeline Update 2007
| May 2007 |
£1,195 |
Lung Cancer Drug Pipeline Update 2007
| May 2007 |
£1,195 |
Analytical Tool - Hematological Cancers
| May 2007 |
£4,740 |
Analytical Tool - Analysis of Cancer Immunotherapy
The World Guide
| May 2007 |
£3,945 |
Bladder Cancer Drug Pipeline Update 2007
| May 2007 |
£795 |
Liver Cancer Drug Pipeline Update 2007
| May 2007 |
£795 |
Pancreatic Cancer Drug Pipeline Update 2007
| May 2007 |
£1,195 |
Renal Cancer Drug Pipeline Update 2007
| May 2007 |
£1,195 |
Melanoma Drug Pipeline Update 2007
| May 2007 |
£1,195 |
Antibodies in Oncology
Drug Pipeline Update 2007
| May 2007 |
£1,195 |
Breast Cancer Drug Pipeline Update 2007
| May 2007 |
£1,195 |
Analytical Tool - Lymphoma Therapeutics & Competitive Insights
| May 2007 |
£2,470 |
Colorectal Cancer Drug Pipeline Update 2007
| May 2007 |
£1,195 |
Analytical Tool - Competitive Outlook on Apoptosis in Oncology
| May 2007 |
£2,470 |
Analytical Tool - Competitive Outlook on Cancer Vaccines
| May 2007 |
£2,470 |
Angiogenesis in Oncology
Drug Pipeline Update 2007
| May 2007 |
£1,195 |
Analytical Tool - Leukemia Therapeutics & Competitive Insights
| May 2007 |
£2,470 |
Analytical Tool - Prostate Cancer
A Therapeutic & Competitive Insight
| May 2007 |
£2,470 |
Protein Kinase Inhibitors in Oncology
Drug Pipeline Update 2007
| May 2007 |
£1,195 |
Analytical Tool - Competitive Outlook on Anti-Angiogenesis and Vascular Targeting in Oncology
| May 2007 |
£2,470 |
Brain Cancer Drug Pipeline Update 2007
| May 2007 |
£1,790 |
Global Cancer Focus Company Directory
| Apr 2007 |
£1,555 |
Targeted Therapeutics in Non-Small Cell Lung Cancer
| Apr 2007 |
£1,555 |
Non-Small Cell Lung Cancer Drug Pipeline Update 2007
| Apr 2007 |
£1,195 |
Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma
Limited R&D activity provides opportunity for early-phase pipeline drugs
| Mar 2007 |
£2,000 |
Breast Cancer - Therapeutic And Competitive Insights
| Feb 2007 |
£1,555 |
Innovations in Cancer
Novel Therapeutics, New Diagnostics and Future R&D Strategies
| Feb 2007 |
£1,495 |
Cancer Therapeutics: The Worldwide Market
The Worldwide Market , 2nd Editon
| Feb 2007 |
£1,990 |
Stakeholder Opinions: Melanoma
Lucrative commercial opportunities persist
| Dec 2006 |
£2,000 |
Pipeline Insight: Therapeutic Cancer Vaccines
A turbulent path from bench to bedside
| Dec 2006 |
£6,000 |
Stakeholder Opinions: Gynecological Cancers
Niche opportunities in advanced disease
| Dec 2006 |
£2,000 |
Stakeholder Insight: Pricing and Reimbursement in Oncology
Do payers believe oncology drugs offer good value?
| Dec 2006 |
£6,000 |
Cancer Market Trends 2006 - 2010
Key market forecasts and growth opportunities
| Dec 2006 |
£1,050 |
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology
| Dec 2006 |
£4,125 |
Preclinical Cancer Therapeutics 2007
Decoding Next Generation Drug Targets for Market Success
| Dec 2006 |
£1,600 |
Regulator Perceptions in Cancer
Evolving opinions about the oncology drug approval process
| Nov 2006 |
£1,000 |
Emerging Cancer Vaccine Market, The
2nd Edition
| Nov 2006 |
£1,745 |
Who's Developing What in Drug Delivery?
| Oct 2006 |
£495 |
Pipeline/Commercial Insight: Colorectal Cancer
Shaping the future dynamics of colorectal cancer management
| Oct 2006 |
£8,000 |
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies
More drugs on the market, more targets in the pipeline
| Oct 2006 |
£8,000 |
Stakeholder Insight: Supportive Care in Cancer Treatment
Some first-generation products proving difficult to dislodge
| Oct 2006 |
£8,000 |
previous
